SCHEMBL296231

SCHEMBL296231

CCCCCCCCCC=CC=CC=CC=C/C=C\C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.65
FASN P49327 1/20 0.65
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 1/20 0.57
TSHR P16473 1/20 0.57
CNR1 P21554 2/20 0.55
CNR2 P34972 2/20 0.55
FAAH O00519 2/20 0.54
GMNN O75496 1/20 0.53
USP2 O75604 1/20 0.53
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 1/20 0.53
CYP2C9 P11712 1/20 0.53
ALOX15 P16050 1/20 0.53
APEX1 P27695 1/20 0.53
CYP2C19 P33261 1/20 0.53
RECQL P46063 1/20 0.53
BLM P54132 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10977120 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL15440591 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL3227940 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL8403803 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL10980307 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL18185437 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL7121862 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL22749030 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL20499878 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL14858316 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117789993-A Establishment and application of gastric cancer prediction model based on tongue fur metabolite 浙江省肿瘤医院 2024-03-29 CN claimed
CN-113490753-A Endometrium liquid for predicting success of fertility treatment 生育实验室科学有限责任公司 2021-10-08 CN claimed
CN-117500851-A Resin composition, resin sheet, multilayer printed wiring board, and semiconductor device 三菱瓦斯化学株式会社 2024-02-02 CN disclosed
CN-117500850-A Resin composition, resin sheet, multilayer printed wiring board, and semiconductor device 三菱瓦斯化学株式会社 2024-02-02 CN disclosed
CN-113490753-A Endometrium liquid for predicting success of fertility treatment 生育实验室科学有限责任公司 2021-10-08 CN disclosed
US-8680143-B2 Orally active curcuminoid compounds LAILA PHARMACEUTICALS PVT. LTD. (US) 2014-03-25 US disclosed
EP-1702515-B1 Fat or oil composition KAO CORP (JP) 2012-03-14 EP disclosed
US-20110112190-A1 ORALLY ACTIVE CURCUMINOID COMPOUNDS LAILA PHARMACEUTICALS PVT. LTD. (IN) 2011-05-12 US disclosed
US-20110082193-A1 TAXANE DERIVATIVE CONTAINING PHARMACEUTICAL COMPOSITION WITH IMPROVED THERAPEUTIC EFFICACY KYSILKA VLADIMIR 2011-04-07 US disclosed
EP-2294049-A2 ORALLY ACTIVE CURCUMINOID COMPOUNDS Laila Pharmaceuticals Pvt. Ltd. (IN) 2011-03-16 EP disclosed
CN-1679403-B Fat or oil processing food KAO CORP 2010-04-28 CN disclosed
EP-1702515-A2 Fat or oil composition Kao Corporation (JP) 2006-09-20 EP disclosed
CN-1679403-A Fat or oil composition KAO CORP (JP) 2005-10-12 CN disclosed
CN-1204819-C Fat or oil composition KAO CORP (JP) 2005-06-08 CN disclosed
US-20030096867-A1 To increase the HDL (High density lipoproteins) cholesterol level in blood for prophylaxis of arteriosclerosis KAO CORPORATION (JP) 2003-05-22 US disclosed
US-6495536-B1 HIGH CONTENT OF DIACYLGLYCEROL; PHYTOSTEROL ADDED; EDIBLE OIL; REDUCING ARTERIOSCLEROTIC FACTORS IN BLOOD; PREVENTION OF ARTERIOSCLEROSIS AND VARIOUS DEGENERATIVE DISEASES KAO CORPORATION (JP) 2002-12-17 US disclosed
CN-1370050-A Fat or oil composition KAO CORP (JP) 2002-09-18 CN disclosed
EP-0437520-B1 TRIGLYCERIDE AND NUTRITIONAL COMPOSITION COMPRISING SUCH TRIGLYCERIDE NOVO NORDISK A/S (DK) 1992-04-15 EP disclosed
EP-0437520-A1 TRIGLYCERIDE AND NUTRITIONAL COMPOSITION COMPRISING SUCH TRIGLYCERIDE. NOVO NORDISK AS (DK) 1991-07-24 EP disclosed
WO-1990004010-A1 TRIGLYCERIDE, NUTRITIONAL COMPOSITION COMPRISING SUCH TRIGLYCERIDE, AND USE OF THE NUTRITIONAL COMPOSITION FOR NUTRITION NOVO NORDISK A/S (DK) 1990-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112190-A1 ORALLY ACTIVE CURCUMINOID COMPOUNDS ALOX12, ALOX15, ALOX15B PTPN1 4616/4885FASN 65/4885KDM4E 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.